Cancer Biotherapy and Radiopharmaceuticals, an esteemed publication by Mary Ann Liebert, Inc., is a premier journal in the field of oncology that addresses the evolving landscape of cancer treatment through innovative biotherapeutics and radiopharmaceutical interventions. With an ISSN of 1084-9785 and an E-ISSN of 1557-8852, this journal provides a vital platform for researchers, clinicians, and industry experts to share cutting-edge findings and methodologies that shape cancer therapeutic practices. Its impressive impact factor and Scopus ranks highlight its significant contribution to the field, particularly within the categories of Oncology and Radiology, where it consistently secures a position in the upper quartiles. As an open access journal, it enables free dissemination of knowledge, ensuring accessibility for a global audience. By focusing on clinical applications, experimental research, and the latest technological advancements, Cancer Biotherapy and Radiopharmaceuticals serves not only as a repository of knowledge but also as a catalyst for future research and development in cancer therapy, making it an invaluable resource for the academic community and healthcare professionals alike.

CURRENT TREATMENT OPTIONS IN ONCOLOGY, published by Springer, is a premier academic journal dedicated to disseminating cutting-edge research and advancements in the field of oncology and pharmacology. With a commendable impact factor and ranked in the Q1 category in both oncology and pharmacology for 2023, this journal positions itself as a leading resource for researchers, healthcare professionals, and students alike, offering insightful reviews and original articles that critically evaluate treatment methodologies and clinical practices. Covering a wide scope of topics from early detection to innovative therapies, it fosters the translation of research findings into clinical applications. With its convergence years spanning from 2000 to 2024, CURRENT TREATMENT OPTIONS IN ONCOLOGY continues to be at the forefront of oncological research, providing a platform for scholars to explore the latest therapeutic options and improve patient outcomes. Highly regarded in the academic community, this journal is essential for anyone looking to stay informed about the dynamic landscape of cancer treatment.

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.

The Journal of Gastrointestinal Oncology, published by AME Publishing Company, is a leading open-access journal that focuses on the complex interplay between gastroenterology and oncology. Established in 2012 and converging into a reputable academic platform through 2024, the journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and management of gastrointestinal cancers. With an ISSN of 2078-6891 and an E-ISSN of 2219-679X, this journal presents articles that are rigorously peer-reviewed, ensuring high-quality content that meets the demands of the scientific community. Despite its current categorization in the Q3 quartile for both Gastroenterology and Oncology as of 2023, it consistently strives to improve its impact and relevance, reflected in its Scopus rankings and percentile metrics. Publishing noteworthy research, reviews, and case studies, the Journal of Gastrointestinal Oncology is instrumental in addressing significant challenges in the field, making it a must-read for those dedicated to advancing knowledge and practice in gastrointestinal oncology.

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.